首页> 美国卫生研究院文献>Scientific Reports >High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals
【2h】

High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals

机译:高密度Huh7.5细胞中空纤维生物反应器培养物用于丙型肝炎病毒的高产量生产和抗病毒药的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chronic hepatitis C virus (HCV) infection poses a serious global public health burden. Despite the recent development of effective treatments there is a large unmet need for a prophylactic vaccine. Further, antiviral resistance might compromise treatment efficiency in the future. HCV cell culture systems are typically based on Huh7 and derived hepatoma cell lines cultured in monolayers. However, efficient high cell density culture systems for high-yield HCV production and studies of antivirals are lacking. We established a system based on Huh7.5 cells cultured in a hollow fiber bioreactor in the presence or absence of bovine serum. Using an adapted chimeric genotype 5a virus, we achieved peak HCV infectivity and RNA titers of 7.6 log10 FFU/mL and 10.4 log10 IU/mL, respectively. Bioreactor derived HCV showed high genetic stability, as well as buoyant density, sensitivity to neutralizing antibodies AR3A and AR4A, and dependency on HCV co-receptors CD81 and SR-BI comparable to that of HCV produced in monolayer cell cultures. Using the bioreactor platform, treatment with the NS5A inhibitor daclatasvir resulted in HCV escape mediated by the NS5A resistance substitution Y93H. In conclusion, we established an efficient high cell density HCV culture system with implications for studies of antivirals and vaccine development.
机译:慢性丙型肝炎病毒(HCV)感染构成了严重的全球公共卫生负担。尽管最近已经开发出有效的治疗方法,但是仍然存在对预防性疫苗的大量未满足的需求。此外,抗病毒药耐药性将来可能会损害治疗效率。 HCV细胞培养系统通常基于单层培养的Huh7和衍生的肝癌细胞系。然而,缺乏用于高产量HCV生产和抗病毒药研究的有效的高细胞密度培养系统。我们建立了基于在有或没有牛血清的情况下在中空纤维生物反应器中培养的Huh7.5细胞的系统。使用适应性嵌合基因型5a病毒,我们实现了HCV感染力峰值和RNA滴度分别为7.6 log10 FFU / mL和10.4 log10 IU / mL。生物反应器衍生的HCV显示出高遗传稳定性,浮力密度,对中和抗体AR3A和AR4A的敏感性以及对HCV共受体CD81和SR-BI的依赖性,与单层细胞培养物中产生的HCV相当。使用生物反应器平台,用NS5A抑制剂daclatasvir进行治疗导致了由NS5A抗性取代Y93H介导的HCV逸出。总之,我们建立了有效的高细胞密度HCV培养系统,对抗病毒药物和疫苗开发具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号